Home › Trial NCT06012383
Alvocade® (Bortezomib) Safety and Effectiveness Study
- Trial IDNCT06012383
- StatusCompleted
- PhaseN/A
- Study typeObservational
- SponsorNanoAlvand
- Enrollment57
- Start date2016-07
- ConditionsMultiple Myeloma, Refractory
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.